Veeva Looks To Widen Antitrust Claims Against IQVIA

By Bryan Koenig · February 26, 2020, 7:12 PM EST

Pharmaceutical information technology company Veeva Systems Inc. has moved to update its antitrust monopoly claims with additional products that life sciences data giant IQVIA Inc. has allegedly refused access to....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief

Case Information

Case Title

IQVIA INC.et al v. VEEVA SYSTEMS, INC.

Case Number

Court

New Jersey

Nature of Suit

Other Statutory Actions

Date Filed

January 10, 2017

Case Title

Veeva Systems Inc. v. IQVIA Inc. et al

Case Number

Court

New Jersey

Nature of Suit

Anti-Trust

Date Filed

September 30, 2019

Recent Articles By Bryan

October 21, 2024
PBMs Keep Door Open To Constitutional Riposte Against FTC
October 16, 2024
Caremark, Optum Say FTC Insulin Case Gets PBMs All Wrong
October 15, 2024
'Extraordinary' Blue Cross Deal Includes $2.8B Payout
October 07, 2024
Merck Immune For 'Inflated' Vax Claims To FDA, 3rd Circ. Says
September 06, 2024
Actelion Must Face Tracleer Antitrust Suit With Class Certified
August 28, 2024
Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit
August 14, 2024
Nursing Co. Exec Can't Split Up Fraud, Wage-Fixing Charges
August 12, 2024
9th Circ. Won't Rethink Upending Sutter Health Antitrust Win
July 31, 2024
Inhaler Patents 'Must Be' In Orange Book, Teva Tells Fed. Circ.
July 17, 2024
Heart Doctor's Sham Suit Claims Cut From Antitrust Row